RECRUITING

Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

Talk to us

Conditions

Idiopathic Pulmonary Fibrosis

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose (\[18F\] FDG) and fluorine-18 Displacement Per Atom (\[18F\]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.

Official Title

Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

Quick Facts

Study Start:2020-12-08
Study Completion:2025-06-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04362644

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years to 85 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Age between 40-85 years old.
  2. 2. A diagnosis of IPF that fulfills American Thoracic Society (ATS) / European Respiratory Society (ERS) 2018 consensus criteria within 5 years.
  3. 3. Ability and willingness to give informed consent and adhere to study requirements.
  4. 4. Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) \>0.70.
  5. 5. High or mixed affinity binder for TSPO ligands based on genotyping for single-nucleotide polymorphism (SNP)rs6971.
  1. 1. Acute exacerbation of IPF within \<30 days
  2. 2. Diagnosis of Diabetes Mellitus (Type 1 or Type 2).
  3. 3. Diagnoses of current infection by clinical or microbial assessments.
  4. 4. Treatment for \>14 days within the preceding month with \>20 mg. prednisone (or equivalent) or any treatment during the last month with a cellular immunosuppressant.
  5. 5. Subjects with prior radiation therapy to the thorax.
  6. 6. Women who are pregnant, or who are breastfeeding. IPF is a disease of older adults, and male predominant, so this will not be a frequent consideration.
  7. 7. Severe cardiovascular disease, defined as any of the following within the preceding 12 weeks: acute myocardial infarction or unstable angina, a coronary revascularization procedure, or stroke.
  8. 8. Subjects with known liver disease.
  9. 9. Diagnosis of any active cancer with the exception of basal cell carcinoma of skin.
  10. 10. Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.
  11. 11. Active cigarette smoking or vaping

Contacts and Locations

Study Contact

Jonathan McConathy, MD, PhD
CONTACT
205-996-7115
jmcconathy@uabmc.edu
April Riddle, BSRT
CONTACT
205-934-6504
ariddle@uabmc.edu

Study Locations (Sites)

The University of Alabama at Birmingham
Birmingham, Alabama, 35249
United States

Collaborators and Investigators

Sponsor: University of Alabama at Birmingham

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-12-08
Study Completion Date2025-06-01

Study Record Updates

Study Start Date2020-12-08
Study Completion Date2025-06-01

Terms related to this study

Additional Relevant MeSH Terms

  • Idiopathic Pulmonary Fibrosis